Hormone therapyFDA-approvedSecond-line
Abiraterone
How it works
Blocks the production of testosterone in the body, which can help slow down or stop prostate cancer growth.
Cancer types
Prostate Cancer— All patients
Efficacy
Abiraterone has been shown to significantly improve overall survival and delay disease progression in patients with advanced prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone Acetate May Help Fight Prostate Cancer by Triggering Stress Response | Prostate Cancer | lab-study | AA induced concentration/time-dependent cytotoxicity in LNCaP cells (24 h IC₅₀ = 4.8 μM) and 22Rv1 cells (24 h IC₅₀ = 15.2 μM) and proliferation decreased by 54.1% and 7.3% at 4.8 μM, respectively. | Source → |
| Genetic Link to Abiraterone Dosage Identified in Prostate Cancer Study | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Enzalutamide Show Similar Outcomes in Prostate Cancer | Prostate Cancer | observational | Median overall survival was 36.2 months for both abiraterone and enzalutamide. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Combining Trastuzumab Deruxtecan and Abiraterone Shows Promise in Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Enzalutamide May Offer Better Survival for Prostate Cancer Patients | Prostate Cancer | observational | Enzalutamide-treated patients had longer overall survival in the first-line setting (HR: 0.84) and the second-line setting (HR: 0.88). | Source → |
| New Delivery System for Prostate Cancer Treatment Shows Promise | Prostate Cancer | lab-study | The dissolution study demonstrated significantly higher ABT release from ABT-ssSNEDDS in comparison to free ABT after 2 h in pH 1.2 and 6.8 pH buffer. | Source → |
| Comorbidities Affect Abiraterone Treatment in Prostate Cancer | Prostate Cancer | meta-analysis | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.